<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE paragraph
  PUBLIC "-//IFRS//DTD DITA Paragraph//EN" "../../../../DocTypes/com.ifrs.doctype/dtd/paragraph.dtd">
<paragraph id="IAS41_B38" base="SL33540"><paranum>B38</paranum><prolog><data name="standard_number" value="IASÂ 41"/><data name="paranum" value="B38"/></prolog><body><p id="IAS41_P0815">The Standard requires that a gain or loss arising on initial recognition of a biological asset and from a change in fair value less estimated point&#x2011;of&#x2011;sale costs of a biological asset should be included in net profit or loss<xref keyref="footnotes/IAS41_FN0020" type="fn"/> for the period in which it arises. Those who support this treatment argue that biological transformation is a significant event that should be included in net profit or loss because: </p><ol id="IAS41_L0032" base="SL155369" type="lower-alpha"><li><li_value>(a)</li_value> <p id="IAS41_P0816" base="SL155371">the event is fundamental to understanding an entity&#x2019;s performance; and</p></li><li><li_value>(b)</li_value> <p id="IAS41_P0817" base="SL155373">this is consistent with the accrual basis of accounting.</p></li></ol></body></paragraph>